Repligen (RGEN) Competitors

Qiagen (NYSE:QGEN) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Do institutionals and insiders hold more shares of QGEN or RGEN?

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media favor QGEN or RGEN?

In the previous week, Repligen had 12 more articles in the media than Qiagen. MarketBeat recorded 19 mentions for Repligen and 7 mentions for Qiagen. Repligen's average media sentiment score of 1.06 beat Qiagen's score of 1.00 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation & earnings, QGEN or RGEN?

Qiagen has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$1.97B	4.89	$341.30M	$0.39	107.97
Repligen	$638.76M	12.18	$41.58M	-$0.37	-375.40

Which has more risk and volatility, QGEN or RGEN?

Qiagen has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.

Do analysts rate QGEN or RGEN?

Qiagen presently has a consensus price target of $50.88, indicating a potential upside of 20.82%. Repligen has a consensus price target of $190.25, indicating a potential upside of 36.97%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Repligen	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Is QGEN or RGEN more profitable?

Qiagen has a net margin of 4.73% compared to Repligen's net margin of -3.36%. Qiagen's return on equity of 13.43% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	4.73%	13.43%	8.10%
Repligen	-3.36%	3.90%	2.72%

Does the MarketBeat Community believe in QGEN or RGEN?

Repligen received 161 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.05% of users gave Repligen an outperform vote while only 60.78% of users gave Qiagen an outperform vote.

Company	Underperform	Outperform
Qiagen	Outperform Votes 248 60.78%	Underperform Votes 160 39.22%
Repligen	Outperform Votes 409 68.05%	Underperform Votes 192 31.95%

Summary

Repligen beats Qiagen on 10 of the 18 factors compared between the two stocks.